Finley John David 4
Research Summary
AI-generated summary
PALISADE BIO (PALI) CEO John D. Finley Sells Shares
What Happened
Finley John David (CEO, CFO & Director) reported the settlement/vesting of 335,167 restricted stock units (RSUs) on July 6, 2026, which converted into common shares. To cover tax withholding tied to that RSU vesting, he sold 146,798 shares in the open market on July 7, 2026 for total proceeds of $303,343 (weighted average ≈ $2.07). He also exercised derivative warrants/options for 133 shares on July 7, 2026 by paying $0.70 per share ($93).
Key Details
- Primary transactions: RSU settlement (335,167 shares vested/converted on 2026-07-06) and open-market sale of 146,798 shares on 2026-07-07 for $303,343.
- Sale price: reported as $2.07 (weighted average); actual sale prices ranged $2.045–$2.09 per share (see footnote).
- Small exercise: 133 shares exercised at $0.70 each (total $93) on 2026-07-07.
- Purpose of sale: shares sold to cover tax withholding obligations related to RSU vesting (footnote F3).
- Footnotes of note: F1 = RSUs settled from Feb 9, 2026 grant; F7 = RSU vesting schedule (1/6th on July 6, 2026, then quarterly); F4 = weighted-average sale price disclosure; F2/F10 provide background on other holdings/warrants.
- Filing timing: Form 4 filed July 8, 2026 for transactions on July 6–7, 2026 (timely based on the report).
- Shares owned after transaction: not specified in the excerpt provided in this summary.
Context
This activity is largely administrative: the large share increase came from RSU settlement (an award converting to stock) and the subsequent sale was to satisfy tax withholding—common practice and not necessarily a directional insider buy/sell signal. The small 133-share exercise appears to be a warrant/option exercise (cash paid $93). Derivative entries reporting a $0 disposition reflect conversion/settlement mechanics rather than cash sales.